March 30, 2022
Over 130 digital therapeutics for behavioral health are in the pipeline, but many payers are still sussing out how best to evaluate them and perhaps provide coverage, according to panelists at AMCP 2022. And for all of their advantages, digital therapeutics have some notable limitations and drawbacks.
March 30, 2022
Michael Ciarametaro, MBA, National Pharmaceutical Council National discusses gene therapy and the Medicaid Best Price Rule with MHE during the annual AMCP conference in Chicago.
March 30, 2022
Dupixent (dupilumab) ushered in a new era and a growing number of treatment options has brought awareness to the condition. But the panelists also discussed problems with step therapy, delays and denials of treatment and the lack of a “gold standard” test for diagnosis.
March 29, 2022
Three thousand people are expected to attend the four-day meeting in Chicago. Kali Cyrus, an assistant professor at Johns Hopkins who identifies as Black, female and queer, is leading a session tomorrow on bias.